You are here
Fresenius ups profit forecast on strong growth in generic drugs
GERMAN healthcare group Fresenius on Wednesday toned up its earnings guidance for the year as demand for recently launched generic infusion drugs continued to grow at higher-than-expected rates.
For 2017, it now expects adjusted net income to grow by 19 to 21 per cent,
- CALL +65 6388 3838
- EMAIL firstname.lastname@example.org